Abstract
Background and Objective: Plasma homocysteine (Hcy) levels have been investigated among patients with multiple sclerosis (MS). However, the changes in Hcy levels and the association between Hcy levels and inflammatory/immune/cerebrospinal fluid (CSF) parameters in neuromyelitis optica spectrum disorder (NMOSD) patients have not been investigated yet. Methods: Case data were collected from 97 acute-phase NMOSD patients and 39 stable-phase NMOSD patients. Patients in the acute phase were divided into 2 groups based on the EDSS score with cutoff equal to 4. Hcy levels, immunoglobulins (Ig) A, G, and M, complement 3 and 4, CH50, C-reactive protein, erythrocyte sedimentation rate (ESR), and CSF examination including white blood cells and total protein were determined. Results: No significant differences in Hcy levels are observed between acute-phase and stable-phase NMOSD patients. Hcy and ESR levels were significantly higher in acute-phase NMOSD patients with EDSS score ≥4. Besides, EDSS is positively correlated with Hcy level, ESR, 1/aquaporin-4 titer and Hcy level is negatively correlated with IgM in acute-phase NMOSD patients. Conclusion: Elevated plasma Hcy has the potential to affect the pathogenesis or progression of NMOSD.
References
1.
Wingerchuk
DM
, Banwell
B
, Bennett
JL
, Cabre
P
, Carroll
W
, Chitnis
T
, et al; International Panel for NMO Diagnosis
. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
. Neurology
. 2015
Jul
;85
(2
):177
–89
.
[PubMed]
0028-38782.
Jarius
S
, Paul
F
, Franciotta
D
, Waters
P
, Zipp
F
, Hohlfeld
R
, et al Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica
. Nat Clin Pract Neurol
. 2008
Apr
;4
(4
):202
–14
.
[PubMed]
1745-834X3.
Papadopoulos
MC
, Verkman
AS
. Aquaporin 4 and neuromyelitis optica
. Lancet Neurol
. 2012
Jun
;11
(6
):535
–44
.
[PubMed]
1474-44224.
Jasiak-Zatonska
M
, Kalinowska-Lyszczarz
A
, Michalak
S
, Kozubski
W
. KalinowskaLyszczarz A, Michalak S, Kozubski W. The immunology of neuromyelitis optica-current knowledge, clinical implications, controversies and future perspectives
. Int J Mol Sci
. 2016
Mar
;17
(3
):273
.
[PubMed]
1661-65965.
Kamath
AF
, Chauhan
AK
, Kisucka
J
, Dole
VS
, Loscalzo
J
, Handy
DE
, et al Elevated levels of homocysteine compromise blood-brain barrier integrity in mice
. Blood
. 2006
Jan
;107
(2
):591
–3
.
[PubMed]
0006-49716.
Faraci
FM
, Lentz
SR
. Hyperhomocysteinemia, oxidative stress, and cerebral vascular dysfunction
. Stroke
. 2004
Feb
;35
(2
):345
–7
.
[PubMed]
0039-24997.
Ho
PI
, Ortiz
D
, Rogers
E
, Shea
TB
. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage
. J Neurosci Res
. 2002
Dec
;70
(5
):694
–702
.
[PubMed]
0360-40128.
Dawson
H
, Collins
G
, Pyle
R
, Deep-Dixit
V
, Taub
DD
. The immunoregulatory effects of homocysteine and its intermediates on T-lymphocyte function
. Mech Ageing Dev
. 2004
Feb
;125
(2
):107
–10
.
[PubMed]
0047-63749.
Chang
L
, Zhang
Z
, Li
W
, Dai
J
, Guan
Y
, Wang
X
. Liver-X-receptor activator prevents homocysteine-induced production of IgG antibodies from murine B lymphocytes via the ROS-NF-kappaB pathway
. Biochem Biophys Res Commun
. 2007
Jun
;357
(3
):772
–8
.
[PubMed]
0006-291X10.
Holven
KB
, Halvorsen
B
, Schulz
H
, Aukrust
P
, Ose
L
, Nenseter
MS
. Expression of matrix metalloproteinase-9 in mononuclear cells of hyperhomocysteinaemic subjects
. Eur J Clin Invest
. 2003
Jul
;33
(7
):555
–60
.
[PubMed]
0014-297211.
Mansoor
MA
, Seljeflot
I
, Arnesen
H
, Knudsen
A
, Bates
CJ
, Mishra
G
, et al Endothelial cell adhesion molecules in healthy adults during acute hyperhomocysteinemia and mild hypertriglyceridemia
. Clin Biochem
. 2004
May
;37
(5
):408
–14
.
[PubMed]
0009-912012.
Holven
KB
, Aukrust
P
, Retterstol
K
, Hagve
TA
, Mørkrid
L
, Ose
L
, et al Increased levels of C-reactive protein and interleukin-6 in hyperhomocysteinemic subjects
. Scand J Clin Lab Invest
. 2006
;66
(1
):45
–54
.
[PubMed]
0036-551313.
Besler
HT
, Comoğlu
S
. Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis
. Nutr Neurosci
. 2003
Jun
;6
(3
):189
–96
.
[PubMed]
1028-415X14.
Vrethem
M
, Mattsson
E
, Hebelka
H
, Leerbeck
K
, Osterberg
A
, Landtblom
AM
, et al Increased plasma homocysteine levels without signs of vitamin B12 deficiency in patients with multiple sclerosis assessed by blood and cerebrospinal fluid homocysteine and methylmalonic acid
. Mult Scler
. 2003
Jun
;9
(3
):239
–45
.
[PubMed]
1352-458515.
Ramsaransing
GS
, Fokkema
MR
, Teelken
A
, Arutjunyan
AV
, Koch
M
, De Keyser
J
. Plasma homocysteine levels in multiple sclerosis
. J Neurol Neurosurg Psychiatry
. 2006
Feb
;77
(2
):189
–92
.
[PubMed]
0022-305016.
Sahin
S
, Aksungar
FB
, Topkaya
AE
, Yildiz
Z
, Boru
UT
, Ayalp
S
, et al Increased plasma homocysteine levels in multiple sclerosis
. Mult Scler
. 2007
Aug
;13
(7
):945
–6
.
[PubMed]
1352-458517.
Triantafyllou
N
, Evangelopoulos
ME
, Kimiskidis
VK
, Kararizou
E
, Boufidou
F
, Fountoulakis
KN
, et al Increased plasma homocysteine levels in patients with multiple sclerosis and depression
. Ann Gen Psychiatry
. 2008
Sep
;7
(1
):17
.
[PubMed]
1744-859X18.
Zoccolella
S
, Tortorella
C
, Iaffaldano
P
, Direnzo
V
, D’Onghia
M
, Paolicelli
D
, et al Elevated plasma homocysteine levels in patients with multiple sclerosis are associated with male gender
. J Neurol
. 2012
Oct
;259
(10
):2105
–10
.
[PubMed]
0340-535419.
Guzel
I
, Mungan
S
, Oztekin
ZN
, Ak
F
. Is there an association between the Expanded Disability Status Scale and inflammatory markers in multiple sclerosis?
J Chin Med Assoc
. 2016
Feb
;79
(2
):54
–7
.
[PubMed]
1726-490120.
Oliveira
SR
, Flauzino
T
, Sabino
BS
, Kallaur
AP
, Alfieri
DF
, Kaimen-Maciel
DR
, et al Elevated plasma homocysteine levels are associated with disability progression in patients with multiple sclerosis
. Metab Brain Dis
. 2018
Oct
;33
(5
):1393
–9
.
[PubMed]
0885-749021.
Teunissen
CE
, Killestein
J
, Kragt
JJ
, Polman
CH
, Dijkstra
CD
, Blom
HJ
. Serum homocysteine levels in relation to clinical progression in multiple sclerosis
. J Neurol Neurosurg Psychiatry
. 2008
Dec
;79
(12
):1349
–53
.
[PubMed]
0022-305022.
Kurtzke
JF
. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)
. Neurology
. 1983
Nov
;33
(11
):1444
–52
.
[PubMed]
0028-387823.
Conradsson
D
, Ytterberg
C
, von Koch
L
, Johansson
S
. Changes in disability in people with multiple sclerosis: a 10-year prospective study
. J Neurol
. 2018
Jan
;265
(1
):119
–26
.
[PubMed]
0340-535424.
Sicras-Mainar
A
, Ruíz-Beato
E
, Navarro-Artieda
R
, Maurino
J
. Impact on healthcare resource utilization of multiple sclerosis in Spain
. BMC Health Serv Res
. 2017
Dec
;17
(1
):854
.
[PubMed]
1472-696325.
Harding
KE
, Wardle
M
, Carruthers
R
, Robertson
N
, Zhu
F
, Kingwell
E
, et al Socioeconomic status and disability progression in multiple sclerosis: A multinational study
. Neurology
. 2019
Mar
;92
(13
):e1497
–506
.
[PubMed]
0028-387826.
Malinow
MR
, Bostom
AG
, Krauss
RM
. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association
. Circulation
. 1999
Jan
;99
(1
):178
–82
.
[PubMed]
0009-732227.
Sacco
RL
, Adams
R
, Albers
G
, Alberts
MJ
, Benavente
O
, Furie
K
, et al; American Heart Association/American Stroke Association Council on Stroke
; Council on Cardiovascular Radiology and Intervention
; American Academy of Neurology
. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline
. Circulation
. 2006
Mar
;113
(10
):e409
–49
.
[PubMed]
0009-732228.
Klimovich
VB
. IgM and its receptors: structural and functional aspects
. Biochemistry (Mosc)
. 2011
May
;76
(5
):534
–49
.
[PubMed]
0006-297929.
Kerekes
G
, Szekanecz
Z
, Dér
H
, Sándor
Z
, Lakos
G
, Muszbek
L
, et al Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity
. J Rheumatol
. 2008
Mar
;35
(3
):398
–406
.
[PubMed]
0315-162X30.
Cheng
C
, Jiang
Y
, Chen
X
, Dai
Y
, Kang
Z
, Lu
Z
, et al Clinical, radiographic characteristics and immunomodulating changes in neuromyelitis optica with extensive brain lesions
. BMC Neurol
. 2013
Jul
;13
(1
):72
.
[PubMed]
1471-237731.
Doi
H
, Matsushita
T
, Isobe
N
, Matsuoka
T
, Minohara
M
, Ochi
H
, et al Hypercomplementemia at relapse in patients with anti-aquaporin-4 antibody
. Mult Scler
. 2009
Mar
;15
(3
):304
–10
.
[PubMed]
1352-458532.
Kuroda
H
, Fujihara
K
, Takano
R
, Takai
Y
, Takahashi
T
, Misu
T
, et al Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica
. J Neuroimmunol
. 2013
Jan
;254
(1-2
):178
–82
.
[PubMed]
0165-572833.
Wang
H
, Wang
K
, Wang
C
, Qiu
W
, Lu
Z
, Hu
X
. Increased soluble C5b-9 in CSF of neuromyelitis optica
. Scand J Immunol
. 2014
Feb
;79
(2
):127
–30
.
[PubMed]
0300-947534.
Nytrova
P
, Potlukova
E
, Kemlink
D
, Woodhall
M
, Horakova
D
, Waters
P
, et al Complement activation in patients with neuromyelitis optica
. J Neuroimmunol
. 2014
Sep
;274
(1-2
):185
–91
.
[PubMed]
0165-572835.
Wang
J
, Li
X
, Zhang
DQ
, Yang
CS
, Qi
Y
, Li
MS
, et al Quantitative analysis of aquaporin-4 antibody in longitudinally extensive transverse myelitis
. J Neuroimmunol
. 2015
Jan
;278
:26
–9
.
[PubMed]
0165-572836.
Jarius
S
, Wildemann
B
. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature
. Brain Pathol
. 2013
Nov
;23
(6
):661
–83
.
[PubMed]
1015-6305© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
